Sucampo Pharma Americas, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Phase 3

Completed

Conditions: Chronic Idiopathic Constipation

Interventions: Drug: Placebo
Drug: Lubiprostone

First Posted Date: 2017-03-31

Last Posted Date: 2020-01-14

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 552

Registration Number: NCT03097861

Locations: 🇺🇸
Investigative Site, Richmond, Virginia, United States
🇺🇸
Investigative Sitee, High Point, North Carolina, United States
🇺🇸
Investigative Site 2, Jackson, Tennessee, United States

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

Phase 3

Completed

Conditions: Healthy Volunteers

First Posted Date: 2017-01-05

Last Posted Date: 2020-03-09

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 49

Registration Number: NCT03010631

Locations: 🇺🇸
ICON, San Antonio, Texas, United States

Evaluation of the Safety of Lubiprostone in Pediatric Participants Aged ≥ 6 Years to < 18 Years With Functional Constipation

Phase 3

Completed

Conditions: Constipation - Functional

Interventions: Drug: Lubiprostone

First Posted Date: 2016-05-10

Last Posted Date: 2020-05-15

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 87

Registration Number: NCT02766777

Locations: 🇺🇸
Northwest Arkansas Pediatric Clinic, Fayetteville, Arkansas, United States
🇺🇸
Pioneer Clinical Research, Bellevue, Nebraska, United States
🇺🇸
Methodist Medical Center, Peoria, Illinois, United States

and more 10 locations

Evaluation of the Efficacy and Safety of Lubiprostone in Adults With Mixed or Unsubtyped Irritable Bowel Syndrome

Phase 2

Terminated

Conditions: Irritable Bowel Syndrome

Interventions: Drug: Placebo
Drug: Lubiprostone

First Posted Date: 2015-09-09

Last Posted Date: 2019-12-27

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 71

Registration Number: NCT02544152

Locations: 🇺🇸
E Squared Research, Inc., Huntsville, Alabama, United States
🇺🇸
Inland Empire Liver Foundation, Rialto, California, United States
🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States

and more 12 locations

Cobiprostone for the Prevention of Oral Mucositis in Subjects With Head and Neck Cancer Receiving Concurrent Radiation and Chemotherapy

Phase 2

Terminated

Conditions: Oral Mucositis

Interventions: Drug: Placebo
Drug: Cobiprostone
Drug: Standard Care - Chemotherapy
Radiation: Standard Care - Radiation

First Posted Date: 2015-09-04

Last Posted Date: 2019-12-02

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 47

Registration Number: NCT02542215

Locations: 🇺🇸
Investigational Site, Madison, Wisconsin, United States

Lubiprostone for Children With Constipation

Phase 3

Completed

Conditions: Constipation - Functional

Interventions: Drug: Lubiprostone

First Posted Date: 2014-05-14

Last Posted Date: 2020-01-21

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 419

Registration Number: NCT02138136

Locations: 🇺🇸
Gastrointestinal Associates, PA, Jackson, Mississippi, United States
🇺🇸
Children's Hospital of Pittsburgh UPMC, Pittsburgh, Pennsylvania, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 82 locations

Lubiprostone in Children With Functional Constipation

Phase 3

Completed

Conditions: Constipation - Functional

Interventions: Drug: Lubiprostone
Drug: Placebo

First Posted Date: 2014-01-22

Last Posted Date: 2020-07-21

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 606

Registration Number: NCT02042183

Locations: 🇺🇸
Loma Linda University Health Care, Loma Linda, California, United States
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 113 locations

A Study to Evaluate the Ocular Blood Flow Effects of Unoprostone Isopropyl in Adults With Dry Age-related Macular Degeneration

Phase 2

Completed

Conditions: Dry Age-related Macular Degeneration

Interventions: Drug: unoprostone isopropyl

First Posted Date: 2011-06-23

Last Posted Date: 2019-12-10

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 33

Registration Number: NCT01379560

Locations: 🇦🇹
Medical University of Vienna, Vienna, Austria

Opioid-induced Bowel Dysfunction (OBD) Pivotal Assessment of Lubiprostone (OPAL)

Phase 3

Completed

Conditions: Opioid-induced Bowel Dysfunction

Interventions: Drug: Placebo
Drug: Lubiprostone

First Posted Date: 2011-02-17

Last Posted Date: 2020-02-11

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 439

Registration Number: NCT01298219

Locations: 🇺🇸
Hartwell Research Group, Anderson, South Carolina, United States
🇺🇸
North Alabama Research Center, Athens, Alabama, United States
🇺🇸
Sunstone Medical Research, Medford, Oregon, United States

and more 137 locations

Efficacy and Safety of Cobiprostone in Patients With Portal Hypertension

Phase 2

Terminated

Conditions: Portal Hypertension

Interventions: Drug: Placebo
Drug: Cobiprostone

First Posted Date: 2008-08-19

Last Posted Date: 2019-11-18

Lead Sponsor: Sucampo Pharma Americas, LLC

Target Recruit Count: 9

Registration Number: NCT00737594

Locations: 🇺🇸
University of Texas Southwestern Medical Center, Dallas, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy